PERSEUS (NCT03710603) compared DVRd vs VRd in transplant-eligible newly diagnosed multiple myeloma. DVRd significantly improved PFS, CR rates, and MRD negativity. Sustained MRD negativity (≥12 months) with DVRd correlated with superior 48-month PFS, supporting its NCCN recommendation.
Key Points:
- Research Problem/Question: Evaluate DVRd vs VRd in TE NDMM.
- Methodology: Randomized trial with primary endpoint of PFS.
- Key Findings: DVRd increased sustained MRD negativity rates and improved 48-month PFS.
- Significance/Impact: Establishes DVRd as preferred regimen for TE NDMM.
Conclusion:
In TE NDMM, DVRd induction and maintenance led to high sustained MRD negativity rates and improved long-term outcomes, affirming its role as a standard treatment option.
Authors:
Philippe Moreau, Pieter Sonneveld, Hermann Einsele, Hang Quach, P. Joy Ho, Meral Beksac, Cyrille Hulin, Elisabetta Antaonioli, Xavier Leleu, Silvia Mangiacavalli, Aurore Perrot, Michele Cavo, Angelo Belotti, Annemiek Broijl, Huiling Pei, Jitsuda Sitthi-Amorn, Robin Carson, Meletios Dimopoulos, Paula Rodríguez-Otero, Mario Boccadoro.
Clinical Trial Registration Number: NCT03710603
DOI:10.1200/JCO.2025.43.16_suppl.7501
Abstract #7501
